• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by OptiNose Inc. (Amendment)

    2/13/24 5:16:15 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OPTN alert in real time by email
    SC 13G/A 1 p24-0479sc13ga.htm OPTINOSE, INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     

    OptiNose, Inc.

    (Name of Issuer)
     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)
     

    68404V100

    (CUSIP Number)
     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 10 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 68404V10013G/APage 2 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Acorn Bioventures, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ☒

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    5,067,698 (including 2,210,526 shares of Common Stock issuable upon exercise of warrants)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    5,067,698 (including 2,210,526 shares of Common Stock issuable upon exercise of warrants)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,067,698 (including 2,210,526 shares of Common Stock issuable upon exercise of warrants)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.4%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

     

    CUSIP No. 68404V10013G/APage 3 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Acorn Capital Advisors GP, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ☒

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    5,067,698 (including 2,210,526 shares of Common Stock issuable upon exercise of warrants)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    5,067,698 (including 2,210,526 shares of Common Stock issuable upon exercise of warrants)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,067,698 (including 2,210,526 shares of Common Stock issuable upon exercise of warrants)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.4%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

    CUSIP No. 68404V10013G/APage 4 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Acorn Bioventures 2 L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ☒

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    6,974,310 (including 3,052,631 shares of Common Stock issuable upon exercise of warrants)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    6,974,310 (including 3,052,631 shares of Common Stock issuable upon exercise of warrants)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    6,974,310 (including 3,052,631 shares of Common Stock issuable upon exercise of warrants)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.0%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

    CUSIP No. 68404V10013G/APage 5 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Acorn Capital Advisors GP 2, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ☒

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    6,974,310 (including 3,052,631 shares of Common Stock issuable upon exercise of warrants)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    6,974,310 (including 3,052,631 shares of Common Stock issuable upon exercise of warrants)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    6,974,310 (including 3,052,631 shares of Common Stock issuable upon exercise of warrants)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.0%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

    CUSIP No. 68404V10013G/APage 6 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Anders Hove

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ☒

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States of America

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    12,042,008 (including 5,263,157 shares of Common Stock issuable upon exercise of warrants)*

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    12,042,008 (including 5,263,157 shares of Common Stock issuable upon exercise of warrants)*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    12,042,008 (including 5,263,157 shares of Common Stock issuable upon exercise of warrants)*

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.9%*

    12

    TYPE OF REPORTING PERSON

    IN

             

    * The exercise of the warrants reported herein is subject to a 9.99% beneficial ownership blocker (the "Blocker") and the percentage set forth in row (11) gives effect to the Blocker. Rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon the exercise of the warrants and gives effect to the Blocker.

     

    CUSIP No. 68404V10013G/APage 7 of 10 Pages

     

    Item 1(a). Name of Issuer.
       
      OptiNose, Inc. (the "Issuer")

     

    Item 1(b). Address of Issuer's Principal Executive Offices.
       
     

    1020 Stony Hill Road, Suite 300

    Yardley, PA 19067

     

    Item 2(a). Name of Person Filing.
       
      This statement is filed by:

     

      (i) Acorn Bioventures, L.P. (“Acorn”);
      (ii) Acorn Capital Advisors GP, LLC (“Acorn GP”), which is the sole general partner of Acorn;
      (iii) Acorn Bioventures 2, L.P. (“Acorn 2”);
      (iv) Acorn Capital Advisors GP 2, LLC (“Acorn GP 2”), which is the sole general partner of Acorn 2; and
      (v) Anders Hove (“Hove or “Manager”).

     

      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."  
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.  

     

    Item 2(b). Address of Principal Business Office.
       
      The address of the principal business office of each of the Reporting Persons is 420 Lexington Avenue, Suite 2626, New York, New York 10170

     

    Item 2(c). Place of Organization.
       
      Acorn is a Delaware limited partnership. Acorn GP is a Delaware limited liability company. Acorn 2 is a Delaware limited partnership. Acorn GP 2 is a Delaware limited liability company. Hove is a citizen of the United States of America.

     

    Item 2(d). Title of Class of Securities.
       
      Common stock, $0.001 par value per share (the "Common Stock")

     

    Item 2(e). CUSIP Number.
       
      68404V100

     

    CUSIP No. 68404V10013G/APage 8 of 10 Pages

     

    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:

     

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) ¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

      (g) o

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

      If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please
      specify the type of institution:  

     

    Item 4. Ownership.
       
      The information required by Items 4(a) – (c)  is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each  Reporting Person.  
       
      The percentages set forth herein are calculated based upon 112,311,984 shares of Common Stock outstanding as of November 1, 2023 as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 and filed with the Commission on November 9, 2023, and assumes the exercise of the reported warrants subject to the Blocker where applicable.
       
      Acorn GP is the general partner of Acorn and may be deemed to beneficially own the shares of Common Stock beneficially owned by Acorn.  Acorn GP 2 is the general partner of Acorn 2 and may be deemed to beneficially own the shares of Common Stock beneficially owned by Acorn 2.
       

      The Manager, in his capacity as manager of each of Acorn GP and Acorn GP 2, may be deemed to beneficially own the shares beneficially owned by each of Acorn and Acorn 2.

     

    CUSIP No. 68404V10013G/APage 9 of 10 Pages

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      Not applicable.

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.
       
      Not applicable.

     

    Item 9. Notice of Dissolution of Group.
       
      Not applicable.

     

    Item 10. Certification.
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    CUSIP No. 68404V10013G/APage 10 of 10 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date:  February 13, 2024  
      ACORN BIOVENTURES, L.P.
      By: ACORN CAPITAL ADVISORS GP, LLC, its General Partner
       
      By: /s/ Anders Hove
      Name:  Anders Hove   
      Title:    Manager
       
       
      ACORN CAPITAL ADVISORS GP, LLC
       
      By: /s/ Anders Hove
      Name:  Anders Hove   
      Title:    Manager
       
       
      ACORN BIOVENTURES 2, L.P.
      By: ACORN CAPITAL ADVISORS GP 2, LLC, its General Partner
       
      By: /s/ Anders Hove
      Name:  Anders Hove
      Title:    Manager
       
       
      ACORN CAPITAL ADVISORS GP 2, LLC
       
      By: /s/ Anders Hove
      Name:  Anders Hove   
      Title:    Manager
       
       
      ANDERS HOVE
      /s/ Anders Hove
       

     

     

     

    Get the next $OPTN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OPTN

    DatePrice TargetRatingAnalyst
    3/20/2025Buy → Hold
    Lake Street
    1/3/2025$5.00 → $18.00Buy
    H.C. Wainwright
    3/11/2024$5.00Buy
    H.C. Wainwright
    8/21/2023$3.00Buy
    Lake Street
    10/21/2022$5.00Buy
    Jefferies
    More analyst ratings

    $OPTN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies

      BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty therapies for specialists and community care providers, that address important medical and public health threats, today announced that the Company has completed its acquisition of Optinose, Inc. (NASDAQ:OPTN). This acquisition broadens Paratek's commercial portfolio which now includes both its flagship antibiotic, NUZYRA® (omadacycline), and Optinose's product XHANCE® (fluticasone propionate). "Adding XHANCE to our portfolio is a pivotal first step in achieving our long-term vision to become a multi‑product specialty

      5/21/25 8:26:34 AM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

      Company reports fourth quarter and full year 2024 XHANCE net revenue of $22.4 million and $78.2 million, increases of 13% and 10% compared to prior year periods Company reports 23% prescription growth from third quarter 2024 to fourth quarter 2024 YARDLEY, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended December 31, 2024, and provided recent operational highlights. Fourth Quarter 2024 and Recent Highlights New Prescriptions (NRx) and Total Prescriptions (TRx)An inflection in prescription demand first

      3/26/25 7:00:00 AM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

      YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time. The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to shareholder and other customary closing conditions. The Company now expects to report results for the three- and twelve-month periods ended D

      3/19/25 9:45:38 PM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPTN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by OptiNose Inc.

      SC 13G - OptiNose, Inc. (0001494650) (Subject)

      11/20/24 5:21:26 PM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by OptiNose Inc.

      SC 13G/A - OptiNose, Inc. (0001494650) (Subject)

      11/14/24 4:54:20 PM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by OptiNose Inc.

      SC 13G/A - OptiNose, Inc. (0001494650) (Subject)

      11/12/24 10:32:10 AM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPTN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • OptiNose downgraded by Lake Street

      Lake Street downgraded OptiNose from Buy to Hold

      3/20/25 8:56:55 AM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on OptiNose with a new price target

      H.C. Wainwright reiterated coverage of OptiNose with a rating of Buy and set a new price target of $18.00 from $5.00 previously

      1/3/25 7:58:58 AM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on OptiNose with a new price target

      H.C. Wainwright initiated coverage of OptiNose with a rating of Buy and set a new price target of $5.00

      3/11/24 7:44:36 AM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPTN
    SEC Filings

    See more
    • SEC Form EFFECT filed by OptiNose Inc.

      EFFECT - OptiNose, Inc. (0001494650) (Filer)

      5/22/25 12:15:04 AM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by OptiNose Inc.

      EFFECT - OptiNose, Inc. (0001494650) (Filer)

      5/22/25 12:15:09 AM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by OptiNose Inc.

      EFFECT - OptiNose, Inc. (0001494650) (Filer)

      5/22/25 12:15:06 AM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPTN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Legal Officer & Corp Sec Marino Michael F Iii returned 125,204 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - OptiNose, Inc. (0001494650) (Issuer)

      5/21/25 9:26:54 AM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Kohler Terry returned 30,541 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - OptiNose, Inc. (0001494650) (Issuer)

      5/21/25 9:26:25 AM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Fletcher R John

      4 - OptiNose, Inc. (0001494650) (Issuer)

      5/21/25 9:26:21 AM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPTN
    Leadership Updates

    Live Leadership Updates

    See more
    • Optinose Appoints Terry Kohler as Chief Financial Officer

      YARDLEY, Pa., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Terry Kohler as Chief Financial Officer. Mr. Kohler was most recently the Chief Financial Officer for Verrica Pharmaceuticals, a dermatology therapeutics company, where he supported commercial preparations for the launch of a topical treatment for molluscum contagiosum and research and development pipeline investments. Mr. Kohler is an experienced biotech finance leader with over 20 years of business experience. "We are pleased to add Terry to our leadership team to help guide

      10/7/24 4:59:53 PM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Optinose Announces CEO Transition and Business Update

      YARDLEY, Pa., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Peter Miller has stepped down as Chief Executive Officer and Board member, and that Ramy Mahmoud, MD, MPH has been appointed as Chief Executive Officer and Board member. In announcing his departure, Peter Miller shared, "It has been a privilege working with the amazing group of colleagues at Optinose. I am proud of all that we have accomplished and the impact we continue to make in our mission to improve patients' lives." During Mr. Miller's nearly 13 years as CEO, the Company experienced s

      1/31/23 7:00:00 AM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Optinose Appoints Paul Spence as Chief Commercial Officer

      YARDLEY, Pa., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Paul Spence as Chief Commercial Officer. Mr. Spence was most recently the Senior Vice President of the U.S. Commercial Organization at Nestlé Health Sciences where he built the commercial capabilities for the Aimmune Gastrointestinal and Food Allergy businesses. Mr. Spence has 30 years of experience in the life science and pharmaceuticals industry as a leader responsible for marketing, sales, market access, operations, and supply chain. Prior to joining Nestlé Health Sciences,

      12/15/22 4:30:00 PM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPTN
    Financials

    Live finance-specific insights

    See more
    • Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies

      BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty therapies for specialists and community care providers, that address important medical and public health threats, today announced that the Company has completed its acquisition of Optinose, Inc. (NASDAQ:OPTN). This acquisition broadens Paratek's commercial portfolio which now includes both its flagship antibiotic, NUZYRA® (omadacycline), and Optinose's product XHANCE® (fluticasone propionate). "Adding XHANCE to our portfolio is a pivotal first step in achieving our long-term vision to become a multi‑product specialty

      5/21/25 8:26:34 AM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

      YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time. The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to shareholder and other customary closing conditions. The Company now expects to report results for the three- and twelve-month periods ended D

      3/19/25 9:45:38 PM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)

      Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10‑million‑patient marketAcquisition advances Paratek's vision to become a multi-product company focused on innovative specialty therapies Total transaction value of up to ~$330 million Potential consideration of up to $14 per share, including upfront consideration of $9 per share, representing a 50% premium to Optinose's closing trading price on March 19, 2025 BOSTON and YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ:OPTN) today announced they have entered into a definitive merger agreement under w

      3/19/25 9:25:02 PM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care